irinotecan
E823218
Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
All labels observed (3)
| Label | Occurrences |
|---|---|
| irinotecan canonical | 3 |
| Onivyde | 1 |
| irinotecan is a topoisomerase I inhibitor | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9812320 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: irinotecan Context triple: [aflibercept, usedWith, irinotecan]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
D.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: irinotecan Target entity description: Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
D.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
camptothecin derivative
ⓘ
chemotherapy drug ⓘ prodrug ⓘ topoisomerase I inhibitor ⓘ |
| hasActiveMetabolite | SN-38 ⓘ |
| hasApprovalYear | 1996 ⓘ |
| hasATCCode | L01CE02 ⓘ |
| hasBlackBoxWarningFor |
myelosuppression
ⓘ
severe diarrhea ⓘ |
| hasCASNumber | 97682-44-5 ⓘ |
| hasCommonSideEffect |
abdominal pain
ⓘ
alopecia ⓘ diarrhea ⓘ nausea ⓘ neutropenia ⓘ vomiting ⓘ |
| hasEliminationRoute |
biliary excretion
ⓘ
fecal excretion ⓘ renal excretion ⓘ |
| hasIndication |
advanced colorectal cancer
ⓘ
cervical cancer ⓘ gastric cancer ⓘ metastatic colorectal cancer ⓘ ovarian cancer ⓘ pancreatic cancer ⓘ small cell lung cancer ⓘ |
| hasIUPACName | (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ⓘ |
| hasMechanismOfAction | inhibition of DNA topoisomerase I ⓘ |
| hasMolecularFormula | C33H38N4O6 ⓘ |
| hasOrigin | semisynthetic derivative of camptothecin ⓘ |
| hasPharmacologicClass |
antineoplastic agent
ⓘ
topoisomerase inhibitor ⓘ |
| hasPregnancyCategory | D (US, historical classification) ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| hasSeriousSideEffect |
severe diarrhea
ⓘ
severe neutropenia ⓘ |
| isAdministeredBy | intravenous infusion ⓘ |
| isComponentOfRegimen |
FOLFIRI
ⓘ
linked to:
FOLFIRI regimen
XELIRI ⓘ |
| isContraindicatedIn |
known hypersensitivity to irinotecan
ⓘ
severe bone marrow suppression ⓘ |
| isInactivatedBy | UGT1A1 ⓘ |
| isMetabolizedBy |
CYP3A4
ⓘ
CYP3A5 ⓘ carboxylesterase enzymes ⓘ |
| isProdrugOf | SN-38 ⓘ |
| isSubstrateOf | P-glycoprotein ⓘ |
| isTeratogenic | yes ⓘ |
| targets | DNA topoisomerase I ⓘ |
| wasApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: irinotecan Description of subject: Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: irinotecan